The annual economic burden among patients hospitalized for community-acquired pneumonia (CAP): a retrospective US cohort study

References

• File TM, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122(2):130–141.
   PubMed Web of Science ®Google Scholar
• Murphy SL, Xu J, Kochanek KD, et al. Mortality in the United States, 2017. NCHS Data Brief. 2018;(328):1–8.
   Google Scholar
• Healthcare Cost and Utilization Project (HCUP). HCUP fast stats – most common diagnoses for inpatient stays. Agency for Healthcare Research and Quality; [cited 2019 Mar]. https://www.hcup-us.ahrq.gov/faststats/NationalDiagnosesServlet
   Google Scholar
• Torio CM, Moore BJ. National inpatient hospital costs: the most expensive conditions by payer, 2013: statistical brief #204. Agency for Healthcare Research and Quality; [cited 2016 May]. https://www.hcup-us.ahrq.gov/reports/statbriefs/sb204-Most-Expensive-Hospital-Conditions.pdf
   Google Scholar
• Sato R, Rey GG, Nelson S, et al. Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged ≥ 50 years. Appl Health Econ Health Policy. 2013;11(3):251–258.
   PubMedGoogle Scholar
• Yu H, Rubin J, Dunning S, et al. Clinical and economic burden of community‐acquired pneumonia in the Medicare fee‐for‐service population. J Am Geriatr Soc. 2012;60(11):2137–2143.
   PubMed Web of Science ®Google Scholar
• Broulette J, Yu H, Pyenson B, et al. The incidence rate and economic burden of community-acquired pneumonia in a working-age population. Am Health Drug benefits. 2013;6(8):494.
   PubMedGoogle Scholar
• Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among US adults. N Engl J Med. 2015;373(5):415–427.
   PubMed Web of Science ®Google Scholar
• Deshpande A, Richter SS, Haessler S, et al. 1469. Microbial etiology of community-acquired pneumonia requiring hospitalization among US adults. Open Forum Infect Dis. 2018;5(suppl_1):S454–S455.
   Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al. IDSA/ATS consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl_2):S27–S72.
   PubMed Web of Science ®Google Scholar
• Cherazard R, Epstein M, Doan TL, et al. Antimicrobial resistant streptococcus pneumoniae: prevalence, mechanisms, and clinical implications. Am J Ther. 2017;24(3):e361–e369.
   PubMed Web of Science ®Google Scholar
• Peyrani P, Mandell L, Torres A, et al. The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance. Expert Rev Respir Med. 2019;13(2):139–152.
   PubMed Web of Science ®Google Scholar
• Pakhale S, Mulpuru S, Verheij TJ, et al. Antibiotics for community-acquired pneumonia in adult outpatients. Cochrane Database Syst Rev. 2014;(10):Cd002109.
   Google Scholar
• Liu HH. Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf. 2010;33(5):353–369.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Drug Safety Communication: FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. [cited 2018 Dec 20]. https://www.fda.gov/Drugs/DrugSafety/ucm628753.htm.
   Google Scholar
• Sakoulas G. Adverse effects of fluoroquinolones: where do we stand? NEJM J Watch. [cited 2019 Feb 13]. https://www.jwatch.org/na48248/2019/02/13/adverse-effects-fluoroquinolones-where-do-we-stand
   Google Scholar
• European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. [cited 2018 Nov 16]. https://www.ema.europa.eu/en/documents/press-release/disabling-potentially-permanent-side-effects-lead-suspension-restrictions-quinolone-fluoroquinolone_en.pdf
   Google Scholar
• Bonafede MM, Suaya JA, Wilson KL, et al. Incidence and cost of CAP in a large working-age population. Am J Manag Care. 2012;18(7):380–387.
   PubMed Web of Science ®Google Scholar
• McLaughlin JM, Johnson MH, Kagan SA, et al. Clinical and economic burden of community-acquired pneumonia in the Veterans Health Administration, 2011: a retrospective cohort study. Infection. 2015;43(6):671–680.
   PubMed Web of Science ®Google Scholar
• Llop CJ, Tuttle E, Tillotson GS, et al. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study. Hosp Pract. 2017;45(1):1–8.
   PubMedGoogle Scholar
• Olasupo O, Xiao H, Brown JD. Relative clinical and cost burden of community-acquired pneumonia hospitalizations in older adults in the United States-A cross-sectional analysis. Vaccines (Basel). 2018;6(3):59.
   Web of Science ®Google Scholar
• Brown JD, Harnett J, Chambers R, et al. The relative burden of community-acquired pneumonia hospitalizations in older adults: a retrospective observational study in the United States. BMC Geriatr. 2018;18(1):92.
   PubMed Web of Science ®Google Scholar
• Thomas CP, Ryan M, Chapman JD, et al. Incidence and cost of pneumonia in Medicare beneficiaries. Chest. 2012;142(4):973–981.
   PubMed Web of Science ®Google Scholar
• Rothberg MB, Haessler S, Lagu T, et al. Outcomes of patients with healthcare-associated pneumonia: worse disease or sicker patients? Infect Control Hosp Epidemiol. 2014;35(S3):S107–S115.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. 2013 Measures updates and specifications report: hospital-level 30-day risk-standardized readmission measures for acute myocardial infarction, heart failure, and pneumonia (Version 6.0). [cited 2013 Mar]. https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html
   Google Scholar
• Zilberberg MD, Shorr AF. Epidemiology of healthcare-associated pneumonia (HCAP). Semin Respir Crit Care Med. 2009;30(01):010–015.
   PubMed Web of Science ®Google Scholar
• Ryan K, Karve S, Peeters P, et al. The impact of initial antibiotic treatment failure: real-world insights in healthcare-associated or nosocomial pneumonia. J Infect. 2018;77(1):9–17.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–e111.
   PubMed Web of Science ®Google Scholar
• Oster G, Berger A, Edelsberg J, et al. Initial treatment failure in non-ICU community-acquired pneumonia: risk factors and association with length of stay, total hospital charges, and mortality. J Med Econ. 2013;16(6):809–819.
   PubMedGoogle Scholar
• Lin RY, Nuruzzaman F, Shah SN. Incidence and impact of adverse effects to antibiotics in hospitalized adults with pneumonia. J Hosp Med. 2009;4(2):E7–E15.
   PubMedGoogle Scholar
• Raut M, Schein J, Mody S, et al. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US. Curr Med Res Opin. 2009;25(9):2151–2157.
   PubMed Web of Science ®Google Scholar
• Kozma CM, Dickson M, Raut MK, et al. Economic benefit of a 1-day reduction in hospital stay for community-acquired pneumonia (CAP). J Med Econ. 2010;13(4):719–727.
   PubMedGoogle Scholar
• Athanassa Z, Makris G, Dimopoulos G, et al. Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a meta-analysis. Drugs. 2008;68(17):2469–2481.
   PubMed Web of Science ®Google Scholar
• Kleinman NL, Yu H, Beren IA, et al. Work-related and health care cost burden of community-acquired pneumonia in an employed population. J Occup Environ Med. 2013;55(10):1149–1156.
   PubMed Web of Science ®Google Scholar